STAT3 and hepatocellular carcinoma: Accordingly, STAT3 inhibition in hepatoma cells mitigated the neutrophil‐conditioned medium's suppressive effects on sorafenib efficacy, highlighting a STAT3‐dependent mechanism through which neutrophil‐released soluble factors inhibit sorafenib's therapeutic efficacy (Figure S6E–G, Supporting Information).